1-4 of 4
Epie Boven
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

O6-Methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor–induced resistance against temozolomide in human melanoma cells

Dennis Fontijn, Auke D. Adema, Kishor K. Bhakat, Herbert M. Pinedo, Godefridus J. Peters, Epie Boven
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (10): 2807–2815.
https://doi.org/10.1158/1535-7163.MCT-07-0044
Published: 15 October 2007
View article titled, <em>O</em><sup>6</sup>-Methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor–induced resistance against temozolomide in human melanoma cells
Open the PDF for <em>O</em><sup>6</sup>-Methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor–induced resistance against temozolomide in human melanoma cells in another window
Journal Articles

Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton

Marcel N.A. Bijman, Geerten P. van Nieuw Amerongen, Nancy Laurens, Victor W.M. van Hinsbergh, Epie Boven
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (9): 2348–2357.
https://doi.org/10.1158/1535-7163.MCT-06-0242
Published: 19 September 2006
View article titled, Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton
Open the PDF for Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton in another window
Journal Articles

Gene-directed Enzyme Prodrug Therapy for Osteosarcoma: Sensitization to CPT-11 in Vitro and in Vivo by Adenoviral Delivery of a Gene Encoding Secreted Carboxylesterase-2

Dinja Oosterhoff, M. Adhiambo Witlox, Victor W. van Beusechem, Hidde J. Haisma, Gerard R. Schaap, Johannes Bras, Frank A. Kruyt, Bonnie Molenaar, Epie Boven, Paul I. J. M. Wuisman, Herbert M. Pinedo, Winald R. Gerritsen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2003) 2 (8): 765–771.
Published: 25 August 2003
View article titled, Gene-directed Enzyme Prodrug Therapy for Osteosarcoma: Sensitization to CPT-11 <em>in Vitro</em> and <em>in Vivo</em> by Adenoviral Delivery of a Gene Encoding Secreted Carboxylesterase-2
Open the PDF for Gene-directed Enzyme Prodrug Therapy for Osteosarcoma: Sensitization to CPT-11 <em>in Vitro</em> and <em>in Vivo</em> by Adenoviral Delivery of a Gene Encoding Secreted Carboxylesterase-2 in another window
Journal Articles

Pretreatment Deoxycytidine Kinase Levels Predict in Vivo Gemcitabine Sensitivity

Judith R. Kroep, Willem J. P. Loves, Clasina L. van der Wilt, Enrique Alvarez, Iannis Talianidis, Epie Boven, Boudewijn J. M. Braakhuis, Cornelis J. van Groeningen, Herbert M. Pinedo, Godefridus J. Peters
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2002) 1 (6): 371–376.
Published: 01 April 2002
View article titled, Pretreatment Deoxycytidine Kinase Levels Predict <em>in Vivo</em> Gemcitabine Sensitivity
Open the PDF for Pretreatment Deoxycytidine Kinase Levels Predict <em>in Vivo</em> Gemcitabine Sensitivity in another window